Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Cardiology, Peking University First Hospital, Beijing, China.
Clin Chim Acta. 2024 Jun 15;560:119730. doi: 10.1016/j.cca.2024.119730. Epub 2024 May 27.
The association between S-adenosylhomocysteine (SAH) and stroke has not been confirmed due to the specialized equipment and time requirements necessary for S-adenosylhomocysteine testing. We aimed to explore the association between SAH and stroke.
A nested, case-control study drawn from the China Stroke Primary Prevention Trial of rural adults with hypertension, including 557 first stroke cases and 557 matched controls was conducted. Serum SAH was measured by stable-isotope dilution liquid chromatography-tandem mass spectrometry using 4500MD. Multiple conditional logistic regression models were used to evaluate the association between SAH and first stroke.
In females, SAH levels were significantly higher in the stroke population than in the control group (16.0 ng/mL vs. 14.6 ng/mL). When SAH was assessed as quartiles, the odds of stroke were 1.78 (95 % CI: 1.02-3.09) in Quartile 2, 1.31 (95 % CI: 0.73-2.33) in Quartile 3, and 1.93 (95 % CI: 1.03-3.62) in Quartile 4, compared to Quartile 1. When Quartiles 2-4 were combined, the adjusted odds ratio of first stroke was 1.64 (95 % CI: 1.03-2.62) compared with Quartile 1. In subgroup analysis, a significant SAH-stroke association was observed in the lower vitamin D3 group (OR = 3.35, 95 % CI:1.72-6.53; P interaction, 0.035). In males, higher levels of SAH were associated with an increased risk of stroke in those under age 60. Compared with the reference group, the adjusted odds ratio of total stroke was 2.40 (95 % CI: 1.02-5.91) in the combined group (Quartile 2-4). In contrast, no significant association between SAH and stroke was found in males aged 60 or older.
This study reveals that SAH is associated with a higher risk of stroke independently of homocysteine, especially in females. SAH may be a second predictor of stroke in the metabolic pathway of methionine, after homocysteine.
由于 S-腺苷同型半胱氨酸(SAH)检测需要专门的设备和时间,因此其与中风之间的关联尚未得到证实。本研究旨在探讨 SAH 与中风之间的关联。
采用巢式病例对照研究设计,从中国农村高血压人群脑卒中一级预防试验中选取了 557 例首发脑卒中患者和 557 例匹配对照。采用稳定同位素稀释液相色谱串联质谱法检测血清 SAH,检测方法为 4500MD。采用多条件 logistic 回归模型评估 SAH 与首发脑卒中之间的关系。
在女性中,脑卒中组的 SAH 水平明显高于对照组(16.0ng/mL 比 14.6ng/mL)。当将 SAH 评估为四分位数时,第 2 四分位数(OR=1.78,95%CI:1.02-3.09)、第 3 四分位数(OR=1.31,95%CI:0.73-2.33)和第 4 四分位数(OR=1.93,95%CI:1.03-3.62)的脑卒中发病风险均高于第 1 四分位数。将第 2-4 四分位数合并后,与第 1 四分位相比,首次脑卒中的调整后比值比为 1.64(95%CI:1.03-2.62)。在亚组分析中,在维生素 D3 水平较低的人群中,SAH 与脑卒中之间存在显著的关联(OR=3.35,95%CI:1.72-6.53;P 交互,0.035)。在男性中,60 岁以下人群中,较高水平的 SAH 与脑卒中风险增加相关。与参考组相比,合并组(第 2-4 四分位数)的总脑卒中的调整后比值比为 2.40(95%CI:1.02-5.91)。相反,在 60 岁及以上的男性中,SAH 与脑卒中之间没有显著关联。
本研究表明,SAH 与脑卒中风险升高独立相关,尤其是在女性中。SAH 可能是蛋氨酸代谢途径中除同型半胱氨酸以外的第二个脑卒中预测因子。